Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis

Gaurav Goyal, MBBS, Marie Hu, MD, Jithma P. Abeykoon, MD, Nora N Bennani, MD, Jay H Ryu, MD, Mithun Vinod Shah, MD PhD, Robert Vassallo, MD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 4189.

https://doi.org/10.1182/blood-2019-122334

Published: 2019

Journal Articles

Clinical Features of Folliculotrophic Mycosis Fungoides

Wang Casey, MD, Rakhshandra Talpur, MD, Silvia Alberti-Violetti, MD, Iris Wieser, MD, Casey Tran, Madeleine Duvic, MD

Blood (2015) 126 (23): 1488.

https://doi.org/10.1182/blood.V126.23.1488.1488

Published: 2015

Journal Articles

Primary Cutaneous Small to Medium-Size CD4+ Pleomorphic T-Cell Lymphoma: 48 Patients from Two Independent Centers and Revaluation of Clinico-Histological Criteria for Differential Diagnosis from Other CTCL

Silvia Alberti-Violetti, MD, Rakhshandra Talpur, MD, Carlos Antonio Torres-Cabala, MD, Laura Corti, PhD, Emilio Berti, MD, Madeleine Duvic, MD

Blood (2014) 124 (21): 2986.

https://doi.org/10.1182/blood.V124.21.2986.2986

Published: 2014

Journal Articles

ONC201/TIC10 Is Effective As a Monoagent and Synergizes with Chemotherapy to Induce Cell Death in Non-Hodgkin Lymphoma

Mala K. Talekar, MD, Josh Allen, PhD, David T. Dicker, Wafik S. El-Deiry, MD PhD FACP

Blood (2014) 124 (21): 5491.

https://doi.org/10.1182/blood.V124.21.5491.5491

Published: 2014

Journal Articles

Array-Based Genomic and Transcriptomic Profiling in Pediatric Acute Leukemias in Search of Genes Responsible for Cyclophosphamide Resistance

Joanna Szczepanek, Joanna Laskowska, Joanna Lewandowska-Bieniek, Andrzej Tretyn, Jan Styczynski, MD PhD

Blood (2014) 124 (21): 3802.

https://doi.org/10.1182/blood.V124.21.3802.3802

Published: 2014

Journal Articles

Bendamustine Is Not Associated With An Increase In Infections – Systematic Review and Meta-Analysis Of Randomized Controlled Trials

Anat Gafter-Gvili, MD, Ronit Gurion, MD, Pia Raanani, MD, Ofer Shpilberg, MD, MPH, Liat Vidal, MD MSc

Blood (2013) 122 (21): 5125.

https://doi.org/10.1182/blood.V122.21.5125.5125

Published: 2013

Journal Articles

Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

Blood (2013) 122 (21): 1974.

https://doi.org/10.1182/blood.V122.21.1974.1974

Published: 2013

Journal Articles

Targeting Glucose Metabolism and Compensatory Metabolic Resistance in Chronic Lymphocytic Leukemia

Kehinde U.A. Adekola, MBBS, Vivian Liu, Shuo Ma, MD, PhD, Steven T. Rosen, MD, FRCPA, Mala Shanmugam, PhD

Blood (2012) 120 (21): 1801.

https://doi.org/10.1182/blood.V120.21.1801.1801

Published: 2012

Journal Articles

Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia

Juliana M Benito, PhD, Hongbo Lu, William R Wilson, PhD, Teresa J Melink, NP, MSN, Jennie Bretz, Sergej Konoplev, MD, PhD, Elihu H. Estey, MD, Hagop M. Kantarjian, MD, John C Gutheil, MD, Michael Andreeff, MD, PhD, Marina Konopleva, M.D., Ph.D.

Blood (2012) 120 (21): 3615.

https://doi.org/10.1182/blood.V120.21.3615.3615

Published: 2012

Journal Articles

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Mazyar Shadman, MD, MPH, Jack M. Lionberger, MD, PhD, Raya Mawad, MD, Ravinder K Sandhu, MD, Carol Dean, RN, Kathleen Shannon-Dorcy, RN, Kyle Wathen, PhD, Bart L Scott, MD, MS, Roland B. Walter, MD, PhD, Pamela S. Becker, MD, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 2622.

https://doi.org/10.1182/blood.V120.21.2622.2622

Published: 2012

Journal Articles

Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

Marina Konopleva, M.D., Ph.D., Gautam Borthakur, Peter F Thall, PhD, Andrew Coveler, MD, Farhad Ravandi, MD, Elias Jabbour, Hoang Q Nguyen, PhD, Juliana M Benito, PhD, Yongchuan Gu, PhD, William R Wilson, PhD, Teresa J Melink, NP, MSN, Hagop M. Kantarjian, John C Gutheil, MD, Elihu H Estey, MD

Blood (2011) 118 (21): 1523.

https://doi.org/10.1182/blood.V118.21.1523.1523

Published: 2011

Journal Articles

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

Blood (2011) 118 (21): 1647.

https://doi.org/10.1182/blood.V118.21.1647.1647

Published: 2011

Journal Articles

Bendamustine for Mantle Cell Lymphoma: Retrospective Analysis of the Spanish Experience

Ana García-Noblejas, MD, Belén Navarro Matilla, MD, Carolina Da Silva Rodriguez, Raquel De Oña Navarrete, MD, María José Ramirez Sánchez, MD, Concepción Nicolás, MD, Ricardo Pérez Fernández, Blanca Sanchez Gonzalez, MD, Eva Domingo-Domènech, MD, Jose Javier Sanchez Blanco, MD, Jimena Cannata-Ortiz, MD, Tomás José González-López, MD, Reyes Arranz Sáez, MD, PhD

Blood (2011) 118 (21): 4942.

https://doi.org/10.1182/blood.V118.21.4942.4942

Published: 2011

Journal Articles

Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104

Blood (2010) 116 (21): 868.

https://doi.org/10.1182/blood.V116.21.868.868

Published: 2010

Journal Articles

Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study.

Blood (2009) 114 (22): 1662.

https://doi.org/10.1182/blood.V114.22.1662.1662

Published: 2009

Journal Articles

A Risk-Adapted, Response-Based Therapeutic Regimen Using a Modified Stanford V Approach for the Treatment of Children with High Risk Hodgkin Lymphoma, AHOPCA LH 2004, a therapeutic regimen from the Central America and Dominican Republic Association of Pediatric Oncology.

E. Mauricio Castellanos, M.D., Monika Metzger, L. Fulgencio Baez, Yessica Gamboa, Armando Pena Hernandez, Soad Alabi, Sandra Luna-Fineman, MD, Rosa Nieves, Pedro de Alarcon, MD

Blood (2009) 114 (22): 718.

https://doi.org/10.1182/blood.V114.22.718.718

Published: 2009

Journal Articles

The DNA Crosslinking Agent SJG-136 (SG2000, BN2629) Is Highly Potent in Acute Myeloid Leukaemia and Is Synergistic with Cytarabine

Elisabeth J Walsby, Alan Burnett, Steven Knapper, Chris Fegan, Chris Pepper

Blood (2008) 112 (11): 4013.

https://doi.org/10.1182/blood.V112.11.4013.4013

Published: 2008

Journal Articles

Design and Characterization of a Novel, Reverse Prodrug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.

James E. Bradner, MD, Edward F. Greenberg, BS, Stuart L. Schreiber, PhD, Ralph Mazitschek, PhD

Blood (2006) 108 (11): 4759.

https://doi.org/10.1182/blood.V108.11.4759.4759

Published: 2006

Journal Articles

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Richard L. Piekarz, MD, PhD, Robin Frye, RN, Maria Turner, MD, John Wright, MD, PhD, Steven Allen, MD, Mark H. Kirschbaum, MD, Jasmine Zain, MD, Miles Prince, MD, Susan E. Bates, MD, for All Collaborators

Blood (2005) 106 (11): 231.

https://doi.org/10.1182/blood.V106.11.231.231

Published: 2005

Journal Articles

Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.

Christopher A. Yasenchak, MD, Ahmet Dogan, MD, PhD, Joseph P. Colgan, MD, Thomas M. Habermann, MD, David J. Inwards, MD, Patrick B. Johnston, MD, PhD, Svetomir N. Markovic, MD, PhD, Ivana N.M. Micallef, MD, Luis F. Porrata, MD, Thomas E. Witzig, MD, Stephen M. Ansell, MD, PhD

Blood (2005) 106 (11): 938.

https://doi.org/10.1182/blood.V106.11.938.938

Published: 2005

NARROW

Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis

Clinical Features of Folliculotrophic Mycosis Fungoides

Primary Cutaneous Small to Medium-Size CD4+ Pleomorphic T-Cell Lymphoma: 48 Patients from Two Independent Centers and Revaluation of Clinico-Histological Criteria for Differential Diagnosis from Other CTCL

ONC201/TIC10 Is Effective As a Monoagent and Synergizes with Chemotherapy to Induce Cell Death in Non-Hodgkin Lymphoma

Array-Based Genomic and Transcriptomic Profiling in Pediatric Acute Leukemias in Search of Genes Responsible for Cyclophosphamide Resistance

Bendamustine Is Not Associated With An Increase In Infections – Systematic Review and Meta-Analysis Of Randomized Controlled Trials

Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

Targeting Glucose Metabolism and Compensatory Metabolic Resistance in Chronic Lymphocytic Leukemia

Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia

Safety and Efficacy of Bendamustine and Idarubicin in Combination Therapy for Patients Age ≥50 with Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome – Results From a Phase I/II Adaptive Design Study.

Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

Bendamustine for Mantle Cell Lymphoma: Retrospective Analysis of the Spanish Experience

Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104

Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study.

A Risk-Adapted, Response-Based Therapeutic Regimen Using a Modified Stanford V Approach for the Treatment of Children with High Risk Hodgkin Lymphoma, AHOPCA LH 2004, a therapeutic regimen from the Central America and Dominican Republic Association of Pediatric Oncology.

The DNA Crosslinking Agent SJG-136 (SG2000, BN2629) Is Highly Potent in Acute Myeloid Leukaemia and Is Synergistic with Cytarabine

Design and Characterization of a Novel, Reverse Prodrug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.

Completion of the First Cohort of Patients with Cutaneous T-Cell Lymphoma Enrolled on a Phase II Trial of Depsipeptide.

Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only